NO976112D0 - 1,6-disubstituerte isokromaner for behandling av migrene - Google Patents

1,6-disubstituerte isokromaner for behandling av migrene

Info

Publication number
NO976112D0
NO976112D0 NO976112A NO976112A NO976112D0 NO 976112 D0 NO976112 D0 NO 976112D0 NO 976112 A NO976112 A NO 976112A NO 976112 A NO976112 A NO 976112A NO 976112 D0 NO976112 D0 NO 976112D0
Authority
NO
Norway
Prior art keywords
isochromes
migraine
disubstituted
treatment
disubstituted isochromes
Prior art date
Application number
NO976112A
Other languages
English (en)
Other versions
NO976112L (no
Inventor
Michael D Ennis
Ruth E Tenbrink
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO976112D0 publication Critical patent/NO976112D0/no
Publication of NO976112L publication Critical patent/NO976112L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO976112A 1995-06-30 1997-12-29 1,6-disubstituerte isokromaner for behandling av migrene NO976112L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74195P 1995-06-30 1995-06-30
US1123496P 1996-02-06 1996-02-06
PCT/US1996/008681 WO1997002259A1 (en) 1995-06-30 1996-06-07 1,6-disubstituted isochromans for treatment of migraine headaches

Publications (2)

Publication Number Publication Date
NO976112D0 true NO976112D0 (no) 1997-12-29
NO976112L NO976112L (no) 1998-03-02

Family

ID=26668092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO976112A NO976112L (no) 1995-06-30 1997-12-29 1,6-disubstituerte isokromaner for behandling av migrene

Country Status (12)

Country Link
EP (1) EP0836599A1 (no)
JP (1) JPH11509532A (no)
AU (1) AU6252296A (no)
BR (1) BR9609631A (no)
CA (1) CA2225282A1 (no)
CZ (1) CZ418597A3 (no)
FI (1) FI974640A7 (no)
MX (1) MX9710260A (no)
NO (1) NO976112L (no)
PL (1) PL324319A1 (no)
SK (1) SK164297A3 (no)
WO (1) WO1997002259A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds
US7335660B2 (en) 2001-12-19 2008-02-26 Eli Lilly And Company Isochroman compounds for treatment of CNS disorders
GB0130339D0 (en) * 2001-12-19 2002-02-06 Lilly Co Eli Isochroman compounds
US7110576B2 (en) 2002-12-30 2006-09-19 Pitney Bowes Inc. System and method for authenticating a mailpiece sender
RU2372344C2 (ru) 2004-05-05 2009-11-10 Ф. Хоффманн-Ля Рош Аг Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого
WO2006066756A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
ATE409179T1 (de) 2004-12-21 2008-10-15 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
CN101119965B (zh) 2004-12-21 2012-09-26 弗·哈夫曼-拉罗切有限公司 萘满和茚满衍生物及其用途
KR100899061B1 (ko) 2004-12-21 2009-05-25 에프. 호프만-라 로슈 아게 테트랄린 및 인단 유도체 및 이의 용도
KR20070088798A (ko) 2004-12-21 2007-08-29 에프. 호프만-라 로슈 아게 크로만 유도체 및 그의 5-ht 수용체 리간드로서의 용도
CN101300246A (zh) 2005-11-03 2008-11-05 弗·哈夫曼-拉罗切有限公司 作为5-ht6抑制剂的芳基磺酰基色满类化合物作为蛋白激酶抑制剂的吲哚基马来酰亚胺衍生物
JP2009541249A (ja) 2006-06-20 2009-11-26 エフ.ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
WO2007147762A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
MX2008015843A (es) 2006-06-20 2009-01-09 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos.
EP2404897A4 (en) * 2009-03-05 2014-02-26 Sumitomo Chemical Co PROCESS FOR PREPARING HALOGEN-SUBSTITUTED BENCHENETIMETHANOL

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552004A (en) * 1976-05-26 1979-09-05 Takeda Chemical Industries Ltd Isochroman derivatives
DE69419778T2 (de) * 1993-12-28 1999-12-09 Pharmacia & Upjohn Co., Kalamazoo Heterozyklische verbindungen für die behandlung von kardiovaskular- und zentralnervensystem störungen

Also Published As

Publication number Publication date
EP0836599A1 (en) 1998-04-22
NO976112L (no) 1998-03-02
SK164297A3 (en) 1998-09-09
FI974640L (fi) 1997-12-30
WO1997002259A1 (en) 1997-01-23
FI974640A0 (fi) 1997-12-30
AU6252296A (en) 1997-02-05
FI974640A7 (fi) 1997-12-30
CZ418597A3 (cs) 1998-06-17
CA2225282A1 (en) 1997-01-23
MX9710260A (es) 1998-03-29
PL324319A1 (en) 1998-05-25
BR9609631A (pt) 1999-03-02
JPH11509532A (ja) 1999-08-24

Similar Documents

Publication Publication Date Title
NO981800D0 (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
FI974640L (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
HUP0004085A3 (en) Novel 3,6-hemiketals from the class of 9a-azalides
FI20011433L (fi) Menetelmä 2,5,diamino-4,6-diklooripyrimidiinin valmistamiseksi
IT1292552B1 (it) Dispositivo per l'applicazione di rivestimenti.
FI973173A0 (fi) Menetelmä kondensaatin käsittelemiseksi
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
NO985535D0 (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO960307D0 (no) Fremgangsmåte ved fremstilling av substituerte 4,6-diamino-5-cyanopyrimidiner
NO179101C (no) Fremgangsmåte for fremstilling av dibeskyttet 2,3-hydroksymetyl-cyklobutanol
FI964829A0 (fi) Menetelmä 2,2,4-trimetyyli-1,3-pentaanidioli-isobutyraatin valmistamiseksi
FI930237A7 (fi) Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
DK0783491T3 (da) Fremgangsmåde til fremstilling af 3,3,5-trichlorglutarimid
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse
FI954263A0 (fi) Vid skjutning anvaendbart foerfarande foer bestaemning av traeffar
FI951660A0 (fi) Foerfarande foer undersoekning av virkes fuktighet
FI954795A0 (fi) Foerfarande foer oekning av en pannas verkningsgrad
RU95117268A (ru) Средство для лечения атопического дерматита
FI940088A0 (fi) Regleranordning/reglerdel foer spolvattenmnaengden i en vattenklosett
FI20040505A7 (fi) Menetelmä 1,3-dihydro-6-hydroksi-2H-indol-2-oni-johdannaisten valmistamiseksi
DK0737068T3 (da) 2,3-diaryl-1-benzopyraner til behandling af dermatitis